Pfizer's breakthrough at-home COVID pill should still work against Omicron, the drug giant insisted today. Laboratory tests suggested the twice-a-day antiviral, called Paxlovid, will still offer a ‘robust’ response against the variant. The company also released final trial data for its medication, saying it cuts the risk of vulnerable adults being hospitalised or dying by up to 90 per cent. The results – taken from a study of 2,200 at-risk ...